US equities |
NVDA $181.60 ▼-9.26% MU $656.39 ▼-17.46% AMD $404.40 ▼-17.26% TSLA $343.69 ▼-10.77% AAPL $344.17 ▼-1.53% SNDK $806.43 ▼-22.26% MSFT $535.93 ▼-3.58% AMZN $260.21 ▼-2.19%
FinancialContent

Tenax Therapeutics, Inc. - Common Stock (NQ:TENX)

1.630 -0.180 (-9.94%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tenax Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Deadline Alert: Tenax Therapeutics, Inc. Stockholders Face December 28, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights
From The Law Offices of Howard G. Smith
Via Business Wire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Deadline Alert: Tenax Therapeutics, Inc. Shareholders Have Until December 28, 2026 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes
From The Law Offices of Frank R. Cruz
Via Business Wire
Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3 ↗
Via Chartmill
News headline image
Did You Lose Money Investing in Tenax Therapeutics, Inc.? Robbins LLP Urges Investors with Large Losses to Contact the Firm for Information About Their Rights Against TENX
San Diego, California--(Newsfile Corp. - November 4, 2026) - Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased... 
Via Newsfile
Topics Lawsuit
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline
From The Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
SueWallSt Reminds Tenax Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 28, 2026 - TENX
A securities fraud class action puts the Tenax promise-reality gap on the record. Management pointed to a 29-meter Phase 2 walk result, while the lawsuit claims TNX-103 was less effective than... 
From SueWallSt
Via GlobeNewswire
News headline image
Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
TENX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Tenax Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
Important Information Regarding Section 20(a) Individual Liability Claims: Tenax's chief executive and three successive chief financial officers face control person claims over allegedly misleading... 
From Levi & Korsinsky, LLP
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
From Levi &amp; Korsinsky, LLP
Via ACCESS Newswire
News headline image
Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline
From The Law Offices of Howard G. Smith
Via Business Wire
News headline image
TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 89.77% Stock Decline
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Rosen Law Firm Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investor Alert: Robbins LLP Informs Investors of the Tenax Therapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case ↗
Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or... 
Via MarketBeat
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Tenax Posts Wider Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
TENX Stock Earnings: Tenax Therapeutics Beats EPS for Q2 2024 ↗
TENX stock results show that Tenax Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >